文献速递前列腺癌

前列腺癌根治性切除术或放疗后1年患者报告的不良反应:一项基于登记数据的全国性研究

Patient-reported Side Effects 1 Year After Radical Prostatectomy or Radiotherapy for Prostate Cancer: A Register-based Nationwide Study.
PubMed 文献 · Eur Urol Oncol · 2024-01-16

该研究基于瑞典前列腺癌数据库,纳入2018年1月1日至2020年12月31日期间接受机器人辅助根治性前列腺切除术(RARP)或放疗(RT)的男性,评估12个月后患者报告的下尿路症状、肠道功能、勃起功能障碍(ED)及生活质量(QoL)。共2557例接受RARP、1741例接受RT。RT与较低尿失禁(OR 0.25)、尿液困扰(OR 0.79)和ED(OR 0.54)风险相关,但肠道症状风险更高(OR 2.86);RARP后QoL更高(OR 1.34)。

要点

  • RT组尿失禁风险低于RARP组(OR 0.25,95%CI 0.19-0.33)。
  • RT组肠道症状风险高于RARP组(OR 2.86,95%CI 2.42-3.39)。
  • RARP组高QoL比例85% vs RT组78%(OR 1.34,95%CI 1.12-1.61)。

核心结论

  • 在该大型非选择性队列中,前列腺癌根治性治疗后短期特异性不良反应在RARP与RT间存在显著差异。
  • RT后尿液困扰风险更低,而RARP后高QoL更常见。

研究设计与样本

  • 瑞典全国性、基于人群的队列研究,纳入2018年1月1日至2020年12月31日期间接受原发性RARP或RT的男性。
  • 共2557例接受RARP,1741例接受RT;采用多变量logistic回归计算绝对比例和比值比(OR),并校正临床特征。

主要发现

  • RARP后13%的男性出现尿失禁,RT后为6%。
  • RARP后18%报告尿液困扰,RT后为18%。
  • RARP后14%报告排便急迫,RT后为34%。
  • 1年时RARP后73%的男性有ED,RT后为77%。
  • RARP后85%报告高QoL,RT后为78%。

关键数值与推荐

  • 多变量回归分析显示,RT与较低的尿失禁风险相关(OR 0.25,95%CI 0.19-0.33)。
  • RT与较低的尿液困扰风险相关(OR 0.79,95%CI 0.66-0.95)。
  • RT与较低的ED风险相关(OR 0.54,95%CI 0.46-0.65)。
  • RT与较高的肠道症状风险相关(OR 2.86,95%CI 2.42-3.39)。
  • RARP后QoL高于RT后(OR 1.34,95%CI 1.12-1.61)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on functional and psychological side effects following curative treatment for prostate cancer are lacking from large, contemporary, unselected, population-based cohorts. OBJECTIVE: To assess urinary symptoms, bowel disturbances, erectile dysfunction (ED), and quality of life (QoL) 12 mo after robot-assisted radical prostatectomy (RARP) and radiotherapy (RT) using patient-reported outcome measures in the Swedish prostate cancer database. DESIGN, SETTING, AND PARTICIPANTS: This was a nationwide, population-based, cohort study in Sweden of men who underwent primary RARP or RT between January 1, 2018 and December 31, 2020. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Absolute proportions and odds ratios (ORs) were calculated using multivariable logistic regression, with adjustment for clinical characteristics. RESULTS AND LIMITATIONS: A total of 2557 men underwent RARP and 1741 received RT. Men who underwent RT were older (69 vs 65 yr) and had more comorbidities at baseline. After RARP, 13% of men experienced incontinence, compared to 6% after RT. The frequency of urinary bother was similar, at 18% after RARP and 18% after RT. Urgency to defecate was reported by 14% of men after RARP and 34% after RT. At 1 yr, 73% of men had ED after RARP, and 77% after RT. High QoL was reported by 85% of men after RARP and 78% of men after RT. On multivariable regression analysis, RT was associated with lower risks of urinary incontinence (OR 0.25, 95% confidence interval [CI] 0.19-0.33), urinary bother (OR 0.79, 95% CI 0.66-0.95), and ED (OR 0.54, 95% CI 0.46-0.65), but higher risk of bowel symptoms (OR 2.86, 95% CI 2.42-3.39). QoL was higher after RARP than after RT (OR 1.34, 95% CI 1.12-1.61). CONCLUSIONS: Short-term specific side effects after curative treatment for prostate cancer significantly differed between RARP and RT in this large and unselected cohort. Nevertheless, the risk of urinary bother was lower after RT, while higher QoL was common after RARP. PATIENT SUMMARY: In our study of patients treated for prostate cancer, urinary bother and overall quality of life are comparable at 1 year after surgical removal of the prostate in comparison to radiotherapy, despite substantial differences in other side effects.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Corsini C, Bergengren O, Carlsson S, et al. Patient-reported Side Effects 1 Year After Radical Prostatectomy or Radiotherapy for Prostate Cancer: A Register-based Nationwide Study. Eur Urol Oncol. 2024. PMID: 38233329. doi:10.1016/j.euo.2023.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。